BioRestorative Therapies Past Earnings Performance
Past criteria checks 0/6
BioRestorative Therapies's earnings have been declining at an average annual rate of -11%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 1.1% per year.
Key information
-11.0%
Earnings growth rate
89.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 1.1% |
| Return on equity | -124.8% |
| Net Margin | -9,887.2% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How BioRestorative Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -14 | 11 | 4 |
| 30 Sep 23 | 0 | -16 | 13 | 4 |
| 30 Jun 23 | 0 | -18 | 14 | 4 |
| 31 Mar 23 | 0 | -19 | 16 | 4 |
| 31 Dec 22 | 0 | -18 | 16 | 4 |
| 30 Sep 22 | 0 | -35 | 15 | 3 |
| 30 Jun 22 | 0 | -34 | 15 | 2 |
| 31 Mar 22 | 0 | -33 | 15 | 1 |
| 31 Dec 21 | 0 | -44 | 26 | 1 |
| 30 Sep 21 | 0 | -30 | 22 | 1 |
| 30 Jun 21 | 0 | -26 | 19 | 1 |
| 31 Mar 21 | 0 | -19 | 16 | 1 |
| 31 Dec 20 | 0 | -11 | 2 | 1 |
| 30 Sep 20 | 0 | -7 | 3 | 1 |
| 30 Jun 20 | 0 | -11 | 4 | 1 |
| 31 Mar 20 | 0 | -18 | 6 | 1 |
| 31 Dec 19 | 0 | -15 | 7 | 2 |
| 30 Sep 19 | 0 | -17 | 7 | 2 |
| 30 Jun 19 | 0 | -15 | 6 | 2 |
| 31 Mar 19 | 0 | -14 | 6 | 2 |
| 31 Dec 18 | 0 | -13 | 6 | 2 |
| 30 Sep 18 | 0 | -11 | 6 | 1 |
| 30 Jun 18 | 0 | -10 | 6 | 2 |
| 31 Mar 18 | 0 | -9 | 6 | 2 |
| 31 Dec 17 | 0 | -9 | 6 | 2 |
| 30 Sep 17 | 0 | -10 | 6 | 3 |
| 30 Jun 17 | 0 | -9 | 6 | 3 |
| 31 Mar 17 | 0 | -9 | 5 | 3 |
| 31 Dec 16 | 0 | -9 | 5 | 3 |
| 30 Sep 16 | 0 | -10 | 6 | 3 |
| 30 Jun 16 | 0 | -9 | 6 | 3 |
| 31 Mar 16 | 0 | -9 | 5 | 3 |
| 31 Dec 15 | 1 | -8 | 5 | 2 |
| 30 Sep 15 | 1 | -6 | 4 | 2 |
| 30 Jun 15 | 1 | -6 | 4 | 2 |
| 31 Mar 15 | 1 | -6 | 4 | 1 |
| 31 Dec 14 | 0 | -6 | 4 | 1 |
| 30 Sep 14 | 0 | -6 | 4 | 1 |
| 30 Jun 14 | 0 | -6 | 4 | 2 |
| 31 Mar 14 | 0 | -6 | 3 | 2 |
| 31 Dec 13 | 0 | -6 | 3 | 2 |
| 30 Sep 13 | 0 | -6 | 4 | 1 |
| 30 Jun 13 | 0 | -6 | 4 | 1 |
Quality Earnings: BRTX is currently unprofitable.
Growing Profit Margin: BRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BRTX is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.
Accelerating Growth: Unable to compare BRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BRTX has a negative Return on Equity (-124.83%), as it is currently unprofitable.